16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

COST-EFFECTIVENESS OF MALE CIRCUMCISION IN SUB-SAHARAN AFRICA

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. TuAc0204

J.G. Kahn¹, E. Marseille², B. Auvert^3
1 University of California, Institute for Health Policy Studies, San Francisco, United States, ² IHPS, UCSF, Health Strategies International, Orinda, United States, ³ Hopital Ambroise-Pare, Assitance Publique, Hopitaux de Paris, Boulogne, INSERM U 687, Saint-Maurice; University Versailles Saint-Quentin, IFR , Villejuif, France

BACKGROUND: A randomized controlled trial of adult male circumcision (MC) conducted in Gauteng Province, South Africa, demonstrated a 60% protective effect against HIV acquisition. This study assesses the cost-effectiveness of an MC intervention to reduce the spread of HIV in sub-Saharan Africa.

METHODS: Cost-effectiveness was modeled for 1000 MCs within a general adult male population. Intervention costs included the MC and treatment of adverse events. HIV prevalence was estimated from published estimates and incidence among susceptible subjects calculated for a steady-state epidemic. Effectiveness was defined as HIV infections averted, estimated by projecting over 20 years the reduction in HIV incidence observed in the trial. Net savings reflect the averted lifetime costs of HIV treatment. Sensitivity analyses examined the effects of input uncertainty and program coverage. Monte Carlo simulations indicated 80% confidence intervals (CI). Results were obtained for the trial province in South Africa and other sub-Saharan settings. Results are discounted to the present at 3% annually.

RESULTS: For Gauteng, South Africa (2005 adult male prevalence of 25.6%), at full MC coverage, each 1000 circumcisions would avert an estimated 308 (80% CI: 189 – 428) infections over 20 years; two-thirds in men and one-third in women. The cost is $181 (80% CI $117 – 306) per HIV infection averted (HIA), and net savings are $2.4 million (80% CI: $1.3 – $3.6 million). Costeffectiveness is sensitive to the costs of MC and of averted HIV treatment, the protective effect of MC, and HIV prevalence. With HIV prevalence of 8.4%, the cost per HIA is $550 (80% CI $318 – $1 200) and net savings are $753 thousand (80%-range: $0.3 – $1.3 million). Cost-effectiveness is insensitive to coverage.

CONCLUSIONS: In settings in sub-Saharan Africa with high or moderate HIV prevalence among the general population, adult male circumcision appears very cost-effective and, when adjusted for averted HIV medical costs, cost-saving.

Download PDF of this abstract.

2006-08-13
TuAc0204

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.